Idiopathic intracranial hypertension
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
For patient information, click here
Template:DiseaseDisorder infobox
Overview
Overview
Idiopathic intracranial hypertension (IIH), sometimes called benign intracranial hypertension (BIH) or pseudotumor cerebri (PTC) is a neurological disorder that is characterized by increased intracranial pressure (ICP), in the absence of a tumor or other diseases affecting the brain or its lining. The main symptoms are headache and visual problems. Diagnosis requires brain scans and lumbar puncture. There are various medical and surgical treatments.
Terminology
The terms “benign” and “pseudotumor” derive from the fact that increased intracranial pressure was, especially in the era before computed tomography (CT), associated by brain tumors. Those patients in whom no tumour was found were therefore diagnosed with “pseudotumor cerebri” (a disease mimicking a brain tumor). The disease was renamed “benign intracranial hypertension” to distinguish it from intracranial hypertension due to malignancy (i.e. cancer); this was also felt to be misleading, and the name was therefore revised to “idiopathic (of no identifiable cause) intracranial hypertension”.[1]
Raised ICP due to another cause (e.g. meningitis, tumor) can be classified as “secondary intracranial hypertension”. The term “intracranial hypertension” is sometimes used (see IHRF) as a blanket term to describe intracranial hypertension of all aetiologies.
Historical Perspective
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- Nonne in 1904 named this disease “pseudotumor cerebri”[1] and Foley named it “benign intracranial hypertension” in 1955.[2]
- They both described it as increased intracranial pressure with no brain tumor. Buchheit et al suggested that the terms “benign” and “pseudtumor” are not appropriate and introduced the name “Idiopathic intracranial hypertesion”.[3]
- For the first time, Walter Dandy described diagnostic criteria for idiopathic intracranial hypertension in 1937 and then modified by in 1985 and Friedman and Jacobson i 2002.[4][5][6]
Landmark Events in the Development of Treatment Strategies
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
Famous Cases
- The first patient with idiopathic intracranial hypertension was introduced by Quincke in 1893. He described 10 cases with headache, papilledema and increased CSF pressure with normal cell count, glucose and protein.[1]
References
- ↑ 1.0 1.1 Pearce JM (December 2009). “From pseudotumour cerebri to idiopathic intracranial hypertension”. Pract Neurol. 9 (6): 353–6. doi:10.1136/jnnp.2009.194837. PMID 19923117.
- ↑ FOLEY J (1955). “Benign forms of intracranial hypertension; toxic and otitic hydrocephalus”. Brain. 78 (1): 1–41. PMID 14378448.
- ↑ Corbett JJ, Thompson HS (October 1989). “The rational management of idiopathic intracranial hypertension”. Arch. Neurol. 46 (10): 1049–51. PMID 2679506.
- ↑ Dandy WE (October 1937). “INTRACRANIAL PRESSURE WITHOUT BRAIN TUMOR: DIAGNOSIS AND TREATMENT”. Ann. Surg. 106 (4): 492–513. PMC 1390605. PMID 17857053.
- ↑ Smith JL (March 1985). “Whence pseudotumor cerebri?”. J Clin Neuroophthalmol. 5 (1): 55–6. PMID 3156890.
- ↑ Friedman DI, Jacobson DM (November 2002). “Diagnostic criteria for idiopathic intracranial hypertension”. Neurology. 59 (10): 1492–5. PMID 12455560.
Classification
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification/Staging
According to the Frisen staging, there are 6 stages of IIH based on the ophthalmoscopic signs:
stage 0
Optic disc is normal but nasal and temporal disc borders are blurred.
stage 1
Increased blurring of the nasal border of optic disc but normal temporal margins.
stage 2
Changes are increase in proportion to stage 1 with elevation of nasal nerve head and temporal border blurring.
stage 3
Changes are increase in proportion to stage 2 with elevation of both nasal and temporal disc border and increased diameter of nerve head.
stage 4
Changes are increase in proportion to stage 3 with nerve head elevation and decreased nerve cup.
stage 5
Increased anterior expansion of nerve head which becomes smooth with dome-shaped appearance.[1]
References
Pathophysiology
Pathophysiology
Pathogenesis
At least two primary mechanisms for the development of increased CSF pressure in primary IIH have been postulated: increased production of CSF and reduced resorption. Increased production may be the result of vasogenic extracellular brain edema, while decreased rebsorption may be due to low conductance of CSF outflow at the arachnoid villi.[2][3] Sørensen et al found evidence for increased water diffusion in the brain of IIH patients when compared to normal subjects.[3] It was argued that this evidence indicates abnormal convective transependymal water flow leading to brain edema. However, this theory remains controversial, as a similar study conducted by Bastin et al that used significantly disparate MR imaging protocols was unable to reproduce these findings.[4] Normal CSF flow involves production at the choroid plexuses and absorption at the cranial and spinal nerve root arachnoid villi and granulations. Impaired CSF absorption at the superior sagittal sinus or along the spinal nerve roots could therefore explain IIH and has been documented in 75-100% of IIH patients.[2] Permeability along the blood-CSF barrier varies, producing an increasing oncotic pressure gradient between the CSF and venous system in a rostral to caudal progression.[5] It is speculated that variations in this oncotic pressure contribute to or impede CSF absorption. The mechanism remains unclear however, since high CSF protein concentrations, as commonly found in Guillain-Barré syndrome or spinal tumors, can manifest as intracranial hypertension, whereas individuals with IIH frequently present with normal-to-low CSF protein findings.[2]
Causes
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Causes
Common causes
Pseudotumor cerebri may be caused by:
- Intracranial venous outflow obstruction (venous sinus thrombosis, head trauma, polycythemia, thrombocytosis)
- Endocrine dysfunction (obesity, cessation of corticosteroid therapy, Addison disease, hypoparathyroidism)
- Vitamin/drug (growth hormone, hypervitaminosis A, tetracycline, minocycline, nalidixic acid)
- Other (chronic hypercapnia, severe right heart failure, chronic meningitis, hypertensive encephalopathy, severe iron deficiency anemia)
- Idiopathic[1]
References
- ↑ Clinical Neurology 9E Aminoff
Differentiating Idiopathic intracranial hypertension from Other Diseases
Differentiating Idiopathic intracranial hypertension from Other Diseases
Epidemiology and Demographics
Epidemiology and Demographics
The reported annual incidence of IIH is <20 per 100,000 persons.[6]
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
The incidence of Pseudotumor cerebri is approximately 1 to 2 per 100,000 population annualy.[1]
Prevalence
The prevalence of Pseudotumor cerebri is approximately 5.1 per 100 000 in the general population in a Spanish study[17raood 2011] and 10.9 per 100 000 in american study. This higher prevalence may reflect the UK increased proportion of obese individuals.[2]
Age and gender
Most of the IIH cases happen in women in child bearing age[3], but it can also happens in children and old adult with male gender. In prepubertal age the gender is not an important risk factor and in old patients the percent of affected males was higher than females.[4][5]
Race
Black patients may have more severe outcome than other population.[6]
References
- ↑ Durcan FJ, Corbett JJ, Wall M (August 1988). “The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana”. Arch. Neurol. 45 (8): 875–7. PMID 3395261.
- ↑ Raoof N, Sharrack B, Pepper IM, Hickman SJ (October 2011). “The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK”. Eur. J. Neurol. 18 (10): 1266–8. doi:10.1111/j.1468-1331.2011.03372.x. PMID 21426442.
- ↑ Wall M, George D (February 1991). “Idiopathic intracranial hypertension. A prospective study of 50 patients”. Brain. 114 ( Pt 1A): 155–80. PMID 1998880.
- ↑ Soler D, Cox T, Bullock P, Calver DM, Robinson RO (January 1998). “Diagnosis and management of benign intracranial hypertension”. Arch. Dis. Child. 78 (1): 89–94. PMC 1717437. PMID 9534686.
- ↑ Bandyopadhyay S, Jacobson DM (March 2002). “Clinical features of late-onset pseudotumor cerebri fulfilling the modified dandy criteria”. J Neuroophthalmol. 22 (1): 9–11. PMID 11937898.
- ↑ Galvin JA, Van Stavern GP (August 2004). “Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center”. J. Neurol. Sci. 223 (2): 157–60. doi:10.1016/j.jns.2004.05.009. PMID 15337617.
Risk Factors
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Risk Factors
The most potent risk factors in the development of IIH are:
Common risk factors
- Age and gender
- Obesity
- Some evidences suggest that obesity can increase intra abdominal and intracranial pressure and have a role in pathogenesis of IIH.[4]
- Positive family history[5]
- Medications
- Systemic illness
Less common risk factors
Drugs such as:
References
- ↑ Wall M, George D (February 1991). “Idiopathic intracranial hypertension. A prospective study of 50 patients”. Brain. 114 ( Pt 1A): 155–80. PMID 1998880.
- ↑ Soler D, Cox T, Bullock P, Calver DM, Robinson RO (January 1998). “Diagnosis and management of benign intracranial hypertension”. Arch. Dis. Child. 78 (1): 89–94. PMC 1717437. PMID 9534686.
- ↑ 3.0 3.1 Bandyopadhyay S, Jacobson DM (March 2002). “Clinical features of late-onset pseudotumor cerebri fulfilling the modified dandy criteria”. J Neuroophthalmol. 22 (1): 9–11. PMID 11937898.
- ↑ Ireland B, Corbett JJ, Wallace RB (March 1990). “The search for causes of idiopathic intracranial hypertension. A preliminary case-control study”. Arch. Neurol. 47 (3): 315–20. PMID 2310315.
- ↑ Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP (June 2014). “The idiopathic intracranial hypertension treatment trial: clinical profile at baseline”. JAMA Neurol. 71 (6): 693–701. doi:10.1001/jamaneurol.2014.133. PMC 4351808. PMID 24756302.
- ↑ Rogers AH, Rogers GL, Bremer DL, McGregor ML (June 1999). “Pseudotumor cerebri in children receiving recombinant human growth hormone”. Ophthalmology. 106 (6): 1186–9, discussion 1189–90. doi:10.1016/S0161-6420(99)90266-X. PMID 10366091.
- ↑ Vischi A, Guerriero S, Giancipoli G, Lorusso V, Sborgia G (2006). “Delayed onset of pseudotumor cerebri syndrome 7 years after starting human recombinant growth hormone treatment”. Eur J Ophthalmol. 16 (1): 178–80. PMID 16496267.
- ↑ 8.0 8.1 8.2 Friedman DI (2005). “Medication-induced intracranial hypertension in dermatology”. Am J Clin Dermatol. 6 (1): 29–37. PMID 15675888.
- ↑ Alexandrakis G, Filatov V, Walsh T (November 1993). “Pseudotumor cerebri in a 12-year-old boy with Addison’s disease”. Am. J. Ophthalmol. 116 (5): 650–1. PMID 8238233.
- ↑ Sheldon RS, Becker WJ, Hanley DA, Culver RL (November 1987). “Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association”. Can J Neurol Sci. 14 (4): 622–5. PMID 3690435.
- ↑ 11.0 11.1 Bruce BB, Kedar S, Van Stavern GP, Corbett JJ, Newman NJ, Biousse V (June 2010). “Atypical idiopathic intracranial hypertension: normal BMI and older patients”. Neurology. 74 (22): 1827–32. doi:10.1212/WNL.0b013e3181e0f838. PMC 2882219. PMID 20513819.
- ↑ Dave S, Longmuir R, Shah VA, Wall M, Lee AG (2008). “Intracranial hypertension in systemic lupus erythematosus”. Semin Ophthalmol. 23 (2): 127–33. doi:10.1080/08820530801888188. PMID 18320479.
- ↑ Celebisoy N, Seçil Y, Akyürekli O (December 2002). “Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey”. Acta Neurol. Scand. 106 (6): 367–70. PMID 12460143.
- ↑ 14.0 14.1 Glueck CJ, Iyengar S, Goldenberg N, Smith LS, Wang P (July 2003). “Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome”. J. Lab. Clin. Med. 142 (1): 35–45. doi:10.1016/S0022-2143(03)00069-6. PMID 12878984.
- ↑ Chang D, Nagamoto G, Smith WE (1992). “Benign intracranial hypertension and chronic renal failure”. Cleve Clin J Med. 59 (4): 419–22. PMID 1525975.
- ↑ Lessell S (1992). “Pediatric pseudotumor cerebri (idiopathic intracranial hypertension)”. Surv Ophthalmol. 37 (3): 155–66. PMID 1475750.
- ↑ Ames D, Wirshing WC, Cokely HT, Lo LL (August 1994). “The natural course of pseudotumor cerebri in lithium-treated patients”. J Clin Psychopharmacol. 14 (4): 286–7. PMID 7962691.
- ↑ Scott IU, Siatkowski RM, Eneyni M, Brodsky MC, Lam BL (August 1997). “Idiopathic intracranial hypertension in children and adolescents”. Am. J. Ophthalmol. 124 (2): 253–5. PMID 9262557.
- ↑ Mushet GR (April 1977). “Pseudotumor and nitrofurantoin therapy”. Arch. Neurol. 34 (4): 257. PMID 843266.
Screening
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for psudotumor cerebri.
Screening
There is insufficient evidence to recommend routine screening for psudotumor cerebri.
References
Natural History, Complications, and Prognosis
Natural History, Complications, and Prognosis
Diagnosis
Diagnosis
The diagnosis may be suspected on the basis of the history and examination. To confirm the diagnosis, as well as excluding alternative causes (such as a brain tumor), several investigations are required; more investigations may be performed if the history is not typical or the patient is more likely to have an alternative problem (e.g. children, the elderly).[6]
Neuroimaging, usually with computed tomography (CT/CAT) or magnetic resonance imaging (MRI), rules out mass lesions. In IIH these scans may be normal, although small or slit-like ventricles and “empty sella sign” (flattening of the pituitary gland due to increased pressure) may be seen. Some propose MRI as preferred mode of imaging in atypical cases, and suggest performance of MR venography to exclude venous obstruction or cerebral venous sinus thrombosis.[6]
Once a mass lesion has been ruled out, lumbar puncture is generally performed to measure the opening pressure, as well as to obtain cerebrospinal fluid to exclude alternative diagnoses such as low-grade viral meningitis. If the opening pressure is increased, CSF may be removed for relief (see below).[6]
Diagnostic Criteria
The original criteria for IIH were described by the American neurosurgeon Walter E. Dandy in 1937.[7] They were modified by Smith in 1985 to become the “modified Dandy criteria”.[8]
| 1 Signs & symptoms of increased ICP – CSF pressure >25 cmH2O |
| 2 No localizing signs with the exception of abducens nerve palsy |
| 3 Normal CSF composition |
| 4 Normal to small (slit) ventricles on imaging with no intracranial mass |
A 2002 review proposed a 6-point set of criteria that required no unexplained symptoms or signs, measurement of the CSF opening pressure in the lateral decubitus (i.e. lying on the side), exclusion of any other causes on specific forms of imaging.[6]
History and Symptoms
Drug Side Effect
Signs and symptoms
Characteristic features of IIH are headache (worse in the morning, associated with nausea) and vision problems, such as double vision, transient visual obscurations, loss of peripheral sight or blurring of vision. If untreated, complete loss of vision is possible. While IIH may develop in any age group and in both males and females, it is more likely in females of fertile age (15-45) who are overweight or obese. Certain medications (hormonal contraception, vitamin A,[9] tetracycline antibiotics) may increase risk of IIH.[6]
Physical findings in IIH are is characterized by papilledema, loss of visual acuity and visual fields, and absence of focal neurological findings (e.g. face, arm or leg weakness, sensory disturbance or coordination loss). Diplopia (double vision), if present, may be due to abducens nerve palsy (the sixth cranial nerve).[6] Absence of papilledema, while making IIH less likely, is possible.[10]
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Treatment
The primary goal in treatment of IIH is the prevention of visual loss and blindness. IIH is treated mainly through the attempted reduction of CSF pressure and, where applicable, weight loss. IIH may resolve after initial treatment, may go into remission and relapse at a later stage, or may continue chronically.[6]
Medical Therapy
Surgery
Surgical treatments include optic nerve sheath decompression and fenestration. In this procedure, a slit is made in the sheath of the optic nerve, which can alleviate swelling and slow or halt loss of vision.[11] Optic nerve sheath fenestration is less effective in controlling the CSF pressure (and in controlling most symptoms, such as headache), but is more effective in protecting the optic nerve from the effects of pressure.
Shunting is a neurosurgical procedure to facilitate the drainage of excess CSF (thereby reducing ICP). A shunt is essentially a silicone tube inserted somewhere in the fluid spaces of the central nervous system, which then drains CSF to the circulatory system or one of the body cavities. There are various types and configurations of shunts; lumboperitoneal (LP) shunts drain from the lumbar spine to the peritoneal cavity, while ventriculoatrial (VA) shunts run from the cerebral ventricles to the heart. Although shunts can dysfunction due to occlusion, infection, malfunction, etc., they are very effective in normalizing CSF pressures. The absence of papilledema or longstanding symptoms make successful shunting less likely.[12] Studies have shown that shunting procedures are becoming more common as the rate of severe obesity rises.[13]
In cases of severe obesity, gastric bypass surgery has been shown to lead to a marked improvement in symptoms.[14]
Prevention
Lumbar puncture
CSF pressure may be temporarily decreased by repeated “therapeutic” (as opposed to diagnostic) lumbar punctures (to remove excessive cerebrospinal fluid). However, this is generally regarded as a “holding measure” until medical or surgical treatment has been instituted.[6][13]
Medication
The best studied medical treatment is the carbonic anhydrase inhibitor acetazolamide, which reduces CSF production.[6] Other drugs such as furosemide and various diuretics, topiramate and prednisone may be used in an attempt to reduce ICP.
References
References
- ↑ Bandyopadhyay S (2001). “Pseudotumor cerebri”. Arch. Neurol. 58 (10): 1699–701. PMID 11594936.
- ↑ 2.0 2.1 2.2 Skau M, Brennum J, Gjerris F, Jensen R (2006). “What is new about idiopathic intracranial hypertension? An updated review of mechanism and treatment”. Cephalalgia. 26 (4): 384–99. doi:10.1111/j.1468-2982.2005.01055.x. PMID 16556239.
- ↑ 3.0 3.1 Sørensen PS, Thomsen C, Gjerris F, Schmidt J, Kjaer L, Henriksen O (1989). “Increased brain water content in pseudotumour cerebri measured by magnetic resonance imaging of brain water self diffusion”. Neurol. Res. 11 (3): 160–4. PMID 2573851.
- ↑ Bastin ME, Sinha S, Farrall AJ, Wardlaw JM, Whittle IR (2003). “Diffuse brain oedema in idiopathic intracranial hypertension: a quantitative magnetic resonance imaging study”. J. Neurol. Neurosurg. Psychiatr. 74 (12): 1693–6. PMID 14638893.
- ↑ Walker RW (2001). “Idiopathic intracranial hypertension: any light on the mechanism of the raised pressure?”. J. Neurol. Neurosurg. Psychiatr. 71 (1): 1–5. PMID 11413251.
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 Friedman, DI (2002). “Diagnostic criteria for idiopathic intracranial hypertension”. Neurology. 59 (10): 1492–1495. PMID 12455560. Unknown parameter
|coauthors=ignored (help) - ↑ Dandy WE (1937). “Intracranial pressure without brain tumor – diagnosis and treatment”. Ann Surg. 106 (4): 492–513. Unknown parameter
|month=ignored (help) - ↑ 8.0 8.1 Smith JL (1985). “Whence pseudotumor cerebri?”. Journal of clinical neuro-ophthalmology. 5 (1): 55–6. PMID 3156890.
- ↑ Jacobson DM, Berg R, Wall M, Digre KB, Corbett JJ, Ellefson RD (1999). “Serum vitamin A concentration is elevated in idiopathic intracranial hypertension”. Neurology. 53 (5): 1114–8. PMID 10496276.
- ↑ Marcelis J, Silberstein SD (1991). “Idiopathic intracranial hypertension without papilledema”. Arch. Neurol. 48 (4): 392–9. PMID 2012512.
- ↑ Banta JT, Farris BK (2000). “Pseudotumor cerebri and optic nerve sheath decompression”. Ophthalmology. 107 (10): 1907–12. PMID 11013197.
- ↑ McGirt MJ, Woodworth G, Thomas G, Miller N, Williams M, Rigamonti D (2004). “Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes”. J. Neurosurg. 101 (4): 627–32. PMID 15481717.
- ↑ 13.0 13.1 Curry WT, Butler WE, Barker FG (2005). “Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002”. Neurosurgery. 57 (1): 97–108, discussion 97–108. PMID 15987545.
- ↑ Sugerman HJ, Felton WL, Sismanis A, Kellum JM, DeMaria EJ, Sugerman EL (1999). “Gastric surgery for pseudotumor cerebri associated with severe obesity”. Ann. Surg. 229 (5): 634–40, discussion 640–2. PMID 10235521.
Template:CNS diseases of the nervous system
de:Pseudotumor cerebri nl:Pseudotumor cerebri sv:Idiopatisk intrakraniell hypertension
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
